BIO-Europe® 2025 - 31th Annual International Partnering Conference
Where partnering becomes the science of connection
Participate in the event designed to make every connection meaningful, targeted, and geared towards achieving breakthroughs in biotech.
BIO-Europe (Fall) brings together the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled partnering meetings, strategic panel discussions and more.
The event convenes over 5,500 attendees, representing over 60 countries and more than 2,800 companies, making the event the industry's largest gathering of biopharma professionals in Europe.
For more information and online registration please visit the conference website at https://informaconnect.com/bioeurope/.
Interested in joining the Belgian Pavilion at BIO-Europe?
Once more, Biovia and Flanders Investment & Trade (FIT) facilitate your participation to the 2025 edition of BIO-Europe (Fall).
Benefits for Flemish companies that join us:
- A 15% discount on the general registration fee per delegate*
- Your logo on the welcome booth
- Your company details in a digital Belgian exhibitor catalogue
- Possibility to distribute your company brochures or gadgets on the booth
- A freely usable seating area on the booth
As a Biovia member and thanks to the partnership with Flanders Investment & Trade, you can enjoy these benefits for a small fee**, but registration through FIT is mandatory.
An overview of registration fees can be found here.
Deadline for registration through FIT: September 22
* Delegation discount will work on All-Access and Digital passes. Careful, the discount can only be provided when registration goes through FIT. Discounts cannot be applied on tickets that have already been purchased.
** SME: 300€; Non-SME: 500€.
---
Session by Biovia member:
IQVIA Institute panel event at BIO Europe hosted by Murray Aitken
Tuesday 4th November, 15:30 – 16:15 CET.
Accessing the U.S. Market: What’s Ahead for European Biotechs?
The U.S. market for medicines has expanded in size and complexity in recent years and represents about 60% of the world market for branded drugs. European biotechs looking to reach patients in the U.S. and benefit from the commercial opportunities in that market have to contend with a range of regulatory, reimbursement and policy complexities. With a new Administration and new leadership in key government agencies in place, understanding the current dynamics is important for investors and biotechs alike. This panel discussion will focus on the implications for biotechs in terms of clinical development program design, accessing the U.S. market, strategic partnership opportunities, and balancing European focus with American opportunity.
Discussion areas will include:
- What are the most significant areas of change underway in the U.S.?
- What are the implications for the biotech sector?
- How are clinical development programs adapting to the Inflation Reduction Act and other FDA-led initiatives?
- How do European Biotechs view U.S. market attractiveness and how has this changed?